MEI Pharma

MEI Pharma is a clinical-stage pharmaceutical company dedicated to developing novel and differentiated cancer therapies aimed at improving patient outcomes. Their approach focuses on evaluating drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address unmet medical needs. MEI Pharma's portfolio includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, a novel small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS). The company is headquartered in San Diego, California.

MEI Pharma is committed to serving society broadly, including the environment, good corporate governance practices, and supporting diversity, equality, and inclusion within the company and the communities they serve. Their mission to develop novel and differentiated cancer therapies is pursued with a strong emphasis on ethics and social responsibility, emphasizing a balanced approach that prioritizes patient well-being and sustainability.

MEI Pharma offers a hybrid work option, allowing employees to balance their work and personal lives. This flexibility, combined with generous paid time off, 12 holidays per year, and five sick days, fosters a positive work-life balance. The company also encourages volunteer time off, demonstrating a commitment to community engagement alongside professional development.

MEI Pharma offers a comprehensive benefits package designed to encourage employee well-being and future investment. Their benefits include health and well-being offerings such as high-deductible and PPO medical plans, vision and dental plans, an Employee Assistance Program, and an Ergonomics Wellness Program. For financial security, they provide a 401(k) savings plan, life insurance, company stock options, and a Professional Development Policy. To encourage work-life balance, they offer paid time off, holidays, sick days, summer hours, a hybrid work option, and volunteer time off.

MEI Pharma is a clinical-stage pharmaceutical company dedicated to developing novel and differentiated cancer therapies that improve patient outcomes. They focus on evaluating drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address unmet medical needs. MEI Pharma's portfolio includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and ME-344, a novel small molecule inhibitor of mitochondrial oxidative phosphorylation.

MEI Pharma cultivates a culture of passion and innovation, valuing dedication to developing novel cancer therapies for patients. They foster a collaborative and creative environment that celebrates diversity and inclusion, recognizing that individual differences are a strength. The company emphasizes personal accountability for superior performance, mutual trust and respect, and fiscal discipline in resource utilization.

MEI Pharma is committed to fostering a diverse and inclusive workplace where everyone is valued and respected. They believe their differences are their strengths and cultivate a culture of collaboration and creativity. Their commitment extends beyond their own company, supporting diversity, equality, and inclusion in the communities where they operate.